UBS Group AG is in talks to sell its hedge fund unit O’Connor to Cantor Fitzgerald LP, a move that would end a more than ...

Cantor Fitzgerald is maintaining a bearish stance on equities, cautioning that the recent market rebound which has been ...

Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker ...

Financial markets have successfully navigated many significant economic disruptions in recent years and the current tariff disruption is likely to be no different. Picture: Getty ...

This week’s Crypto Biz newsletter covers renewed inflows into Bitcoin ETFs, a potential crypto venture backed by Cantor Fitzgerald, and Coinbase’s possible pursuit of a federal banking charter.

Once a niche idea, bitcoin-holding firms have gained traction after the exponential growth of Michael ... Cantor Equity is a special purpose acquisition company (SPAC) backed by Cantor Fitzgerald ...

The deal remains subject to shareholder approval and other standard conditions. Shares of Cantor Equity Partners will continue to trade under the symbol “CEP” until the transaction closes.

A consortium including Japanese technology investor SoftBank Group on Wednesday joined hands with a blank-check firm backed by boutique bank Cantor Fitzgerald ... it said. Michael Saylor's ...

Bond brokerage Cantor Fitzgerald, stablecoin giant Tether and ... into a bitcoin volatility juggernaut by billionaire co-founder Michael Saylor. Thanks to clever financial engineering and leverage ...

Cantor Fitzgerald, SoftBank Group, Tether, and Bitfinex have joined hands to launch Twenty One. The consortium of traditional finance (TradFi) and decentralized finance (DeFi) firms announced on ...

An affiliate of Cantor Fitzgerald LP is teaming up with stablecoin ... the latest company to emulate the business model of Michael Saylor’s Strategy. Twenty One said it expects to launch with ...

On Wednesday, Cantor Fitzgerald reiterated an Overweight rating on shares of Summit Therapeutics plc (NASDAQ:SMMT), following the company’s recent clinical trial updates. The company ...